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Abstract 
Attention-deficit/hyperactivity disorder (ADHD) has become a major aspect of the work of child and adolescent 
psychiatrists and paediatricians in the UK. In Scotland, Child and Adolescent Mental Health Services were required 
to address an increase in referral rates and changes in evidence-based medicine and guidelines without additional 
funding. In response to this, clinicians in Dundee have, over the past 15 years, pioneered the use of integrated psy-
chiatric, paediatric, nursing, occupational therapy, dietetic and psychological care with the development of a clearly 
structured, evidence-based assessment and treatment pathway to provide effective therapy for children and adoles-
cents with ADHD. The Dundee ADHD Clinical Care Pathway (DACCP) uses standard protocols for assessment, titration 
and routine monitoring of clinical care and treatment outcomes, with much of the clinical work being nurse led. 
The DACCP has received international attention and has been used as a template for service development in many 
countries. This review describes the four key stages of the clinical care pathway (referral and pre-assessment; assess-
ment, diagnosis and treatment planning; initiating treatment; and continuing care) and discusses translation of the 
DACCP into other healthcare systems. Tools for healthcare professionals to use or adapt according to their own clinical 
settings are also provided.
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Background
Attention-deficit/hyperactivity disorder (ADHD) is a het-
erogeneous neurodevelopmental disorder with a world-
wide prevalence of 5–7  % in children and adolescents 
[1, 2]; UK prevalence is estimated at 2.2  % [3]. The dis-
order is characterized by core symptoms of inattention, 
hyperactivity and impulsivity [4, 5], and is associated 
with functional impairment [6–8]. In the UK, ADHD 
management is primarily the responsibility of special-
ists based within either paediatric departments or Child 
and Adolescent Mental Health Services (CAMHS). As a 
consequence of an increase in awareness and acceptance 
of ADHD in the UK in recent years, management of this 
disorder has become a major aspect of the work of these 
services [9, 10]. This has required adaptations, usually 
within existing budgets and staffing levels, to accommo-
date this increased workload.
In a 5-year study, most adolescents with ADHD man-
aged in a UK community setting had continuing difficul-
ties despite contact with CAMHS and pharmacotherapy 
[11]; the authors of this report concluded that “the treat-
ment and monitoring of ADHD need to be intensified” 
[11]. This concurs with the findings of the Multimodal 
Treatment Study of Children with ADHD (MTA) [12, 13], 
which showed that a carefully implemented approach to 
medication is superior to routine clinical care. However, 
the use of symptom thresholds or specific impairment 
criteria during ADHD assessment, or standardized or 
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systematic criteria to assess treatment outcomes is still 
limited within UK clinical settings [14, 15].
ADHD treatment guidelines and algorithms, includ-
ing those for England and Wales [16], Scotland [17, 18], 
Europe [19–25], and North America [26–28], have pro-
posed evidence-based approaches for ADHD manage-
ment. However, tools to translate this guidance into 
everyday clinical practice are lacking. While Hill and Tay-
lor published an auditable protocol for treating ADHD 
in 2001 [29] and CADDRA published several toolkits 
to support ADHD practitioners, we are unaware of any 
other detailed descriptions of effective, evidence-based 
pathways that have been developed and implemented 
within a real-world setting. Therefore, we developed 
an implementable evidence-based clinical pathway for 
the assessment and management of ADHD. Here, we 
describe the pathway and provide the protocols and sup-
porting tools necessary for wider use. We hope that the 
information provided will be adapted by others to suit 
their local healthcare service structure and resources.
The Dundee ADHD Clinical Care Pathway
Dundee and Angus are Scottish regions with a broad 
sociodemographic composition, including urban and 
rural areas of both considerable social deprivation and 
relative affluence. Specific clinical services for ADHD in 
the region are managed by the National Health Service 
(NHS) generic CAMHS service and delivered by non-
academic NHS clinicians. Over the last 15 years, Dundee 
CAMHS has developed a clearly structured, evidence-
based clinical pathway for the assessment and manage-
ment of children and adolescents with ADHD in Dundee 
and Angus based on key clinical practice guidelines and 
other publications (Table 1).
The Dundee ADHD Clinical Care Pathway (DACCP) 
was developed to facilitate the dynamic integration of 
new knowledge in order to provide effective, evidence-
based therapy; speed up the transfer of research findings 
into clinical practice; use staff skills and time effectively; 
and provide a consistent approach to the management 
of waiting lists and treatment. The DACCP integrates 
psychiatric, paediatric, nursing, occupational therapy, 
dietetic and psychological care. A key focus of the path-
way is the routine use of standardized protocols for the 
assessment, titration and monitoring of clinical care. 
These protocols incorporate accessible, free or low-cost, 
clinically relevant, well-validated instruments at all stages 
of the pathway. The use of clinical outcome assessments 
to inform day-to-day clinical decision-making is particu-
larly important, and is in keeping with key findings from 
the MTA study [12, 13].
The pathway is dynamic and in continuous develop-
ment; up-to-date, evidence-based approaches to assess-
ment and treatment are implemented into the DACCP as 
quickly as possible. While clinical care is delivered within 
a non-academic, clinical setting, there are close ties with 
the University of Dundee, where staff are heavily involved 
in the generation and evaluation of new evidence to 
advance the management of ADHD and in the devel-
opment of clinical guidelines. These associations have 
undoubtedly played an important part in the develop-
ment and implementation of the pathway. However, we 
believe that having now developed and refined the path-
way over several years it is now ready to be implemented 
in broader settings.
Approximately 800 patients (~1.2 % of the local school-
age population) currently receive care via the DACCP. 
The pathway was formally evaluated in the 2012 Scot-
land-wide audit of ADHD by Health Improvement Scot-
land [15]. This audit found the DACCP to be compliant 
with all of the major recommendations of the Scottish 
Intercollegiate Guidelines Network (SIGN) [18] and the 
National Institute for Clinical Excellence (NICE) [16, 30, 
31] for the assessment and management of ADHD. The 
pathway was highly praised because it demonstrated the 
provision of robust, quality-based, protocol-driven and 
non-profession-specific clinical care [15]. It was also the 
only ADHD pathway in Scotland that routinely measured 
Table 1 Key clinical practice guidelines and other publications used in the development of the DACCP
ADHD attention-deficit/hyperactivity disorder, DACCP Dundee ADHD Clinical Care Pathway
Guidelines
The Scottish Intercollegiate Guidelines Network [17, 18]
National Institute for Clinical Excellence guidelines [16, 30, 31]
Quality Improvement Scotland/Healthcare Improvement Scotland [15, 54, 61]
European guidelines [19–25, 62]
Guidelines and resources from the Canadian Attention Deficit Hyperactivity Disorder Resource Alliance [59]
The Multimodal Treatment Study of Children with ADHD [12, 13, 63–66]
Texas Children’s Medication Algorithm [67, 68]
Scottish Medicines Consortium and National Institute for Clinical Excellence advice on the use of lisdexamfetamine [69, 70]
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clinical outcomes [15]. The pathway has received inter-
national attention and has been used as a template for 
service development in many countries (personal com-
munication, D Coghill).
Stages of the DACCP
The pathway has four key stages, described in detail 
below, and summarized in Fig. 1.
1. Referral and pre‑assessment screening
In approximately 80  % of cases, the information in the 
referral letter is adequate to decide whether a full clini-
cal assessment is warranted. Where insufficient informa-
tion is provided (e.g. clinical problems are unclear or do 
not indicate whether impairment is likely), a ‘direct but 
distant’ approach is used to obtain additional insight 
whenever possible, as it combines accuracy with effi-
cient resource use. Telephone interviews are conducted 
with a parent/carer, followed by a teacher if necessary. 
These are typically conducted by a specialist nurse using 
either the ADHD rating scale IV (ADHD-RS-IV) or the 
ADHD questions from the Swanson, Nolan and Pelham 
(SNAP)-IV questionnaire, delivered as a clinician-rated 
semi-structured interview (Table 2). A mean item score 
(total or sub-scale) of >2 is highly suggestive of ADHD; 
intermediate scores (1–2) require clinical judgement. 
This approach combines good sensitivity (83 %) and bet-
ter specificity (97 %; i.e. fewer false positives) compared 
with the indirect questionnaire-based approach outlined 
below (unpublished observations, D Coghill).
Within the DACCP, we focus on this ‘direct but dis-
tant’ approach; however, where this is not feasible there 
are alternative approaches available for pre-screening 
of referrals, including: indirect contact (e.g. parent-
completed questionnaires, such as the generic Strengths 
and Difficulties Questionnaire [32], or the ADHD-spe-
cific Conners [33], ADHD-RS-IV [34] or SNAP-IV [35] 
questionnaires); and personal assessment using a triage 
approach or the Choice appointments associated with 
the Choice and Partnership Approach (CAPA) model 
[36].
Once a decision has been made to conduct a full assess-
ment, we do not usually request any further pre-assess-
ment parent- or self-completed ADHD questionnaires.
Of note, population-based screening in the DACCP is 
not utilized. In areas where ADHD is under-diagnosed, 
such as Scotland [15], the main purpose of screening is 
to ensure that patients do not go unrecognized. How-
ever, population-based approaches using parent- and/
or teacher-rated questionnaires are associated with high 
false positive rates [37].
Waiting list prioritization
Complex neurodevelopmental disorders (such as 
ADHD, autism spectrum disorders, tic disorders and 
Tourette’s syndrome, as well as learning disorders and 
intellectual impairment) can have a dramatic impact on 
home and family life and it is not uncommon to receive 
requests for prioritization of care. These cases, however, 
typically require different criteria for prioritization to 
other psychiatric disorders. Without appropriate prior-
itization, those with developmental disorders are at risk 
of remaining at the end of the queue. Our service there-
fore runs two parallel prioritization systems (one for 
‘emotional disorders’ and one for ‘developmental disor-
ders’), each with its own prioritization criteria. Examples 
of prioritization criteria for patients with a developmen-
tal disorder are shown in Table  3. Within the DACCP, 
decisions about prioritization are typically conducted by 
specialist nurses, with backup from senior medical staff 
as required.
2. Assessment, diagnosis and treatment planning
The DACCP has developed a standardized protocol for 
assessment, diagnosis and treatment planning, whereby 
initial information gathering is conducted by specialist 
nursing staff, restricting the role of the doctor to diagno-
sis and treatment planning. This facilitates effective use 
of limited clinical resources, improving clinical flow.
2a. Information gathering
The focus at this stage is to collect the information 
required to make a diagnosis and to plan treatment. 
Clinical information is primarily gathered from parents/
carers using a standardized procedure that, in addition 
to ADHD, also considers potential differential diagno-
ses and comorbid mental and physical health problems. 
An interview with the child, focusing on impairment 
and functioning, is also conducted. Structured narra-
tive school reports and teacher-rating scales, most fre-
quently the Swanson, Kotkin, Agler, M-Flynn and Pelham 
(SKAMP) scale [38] (Additional file  1), are requested 
prior to the first assessment visit.
Initial information gathering is completed during one 
or more face-to-face clinical assessment visits using a 
structured assessment document (Additional file 2). Pre-
senting problems, health and developmental history, and 
global functioning are documented, in addition to 
comorbid psychiatric conditions and any issues in the 
patient’s family life, social functioning (including peer 
relationships, criminal behaviour, etc.) and school func-
tioning. Within the DACCP, this assessment is conducted 
by a core CAMHS worker (a nurse, primary mental 
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health worker1 or clinical psychologist); all staff are 
trained in all aspects of the assessment.
A structured assessment of ADHD is performed using 
the ADHD section of the Schedule for Affective Disor-
ders and Schizophrenia for School-Age Children-Present 
and Lifetime version (K-SADS-PL) [39, 40]. Additional 
routine screening questions cover the full range of men-
tal health problems, including; autism spectrum dis-
orders, developmental communication disorders and 
social communication disorder. Standardized screen-
ing questionnaires (summarized in Additional file 3) are 
used to support the identification of common co-existing 
disorders.
A general physical examination, including observation 
of the standard of general care, assessment for stigmata 
of congenital disorders and neurodevelopmental imma-
turity, a vision and hearing check, a screen of gross and 
fine motor functioning and a screen for motor and vocal 
tics, is suggested during the initial assessment. Physi-
cal health (head circumference, height, weight, blood 
pressure and pulse rate) and assessment of cardiac risk 
factors are recorded at assessment (and routinely there-
after). In line with guideline recommendations, routine 
blood tests, electroencephalography or electrocardiogra-
phy are not routinely conducted, unless there is a specific 
indication [20, 23, 24].
Following the interview, additional information (e.g. 
from the patient’s school or other agencies) is requested 
as required. Patients may be referred for additional spe-
cific assessments (e.g. the Autistic Diagnostic Observa-
tion Schedule for autism [41], occupational therapy for 
developmental coordination disorder and/or sensory 
sensitivity, cognitive testing or paediatric assessment for 
physical problems). While cognitive and neuropsycho-
logical testing are not part of the routine assessment, the 
British Picture Vocabulary Scale [42] is utilised routinely 
as an estimate of verbal intelligence.
1 A mental health practitioner who focuses on the interface between pri-
mary and secondary care. Primary mental health workers may have a vari-
ety of professional backgrounds, including nursing, psychology, social work 
and education.
Fig. 1 Flow diagram showing the four stages of the Dundee ADHD 
Clinical Care Pathway. ADHD attention-deficit/hyperactivity disorder, 
ADHD-RS-IV attention-deficit/hyperactivity disorder rating scale IV, 
ADOS Austistic Diagnostic Observation Schedule, ECG electrocardio-
gram, K-SADS-PL Schedule for Affective Disorders and Schizophrenia 
for School-Age Children-Present and Lifetime version, NFPP New 
Forest Parenting Programme, SKAMP Swanson, Kotkin, Agler, M-Flynn 
and Pelham scale, SNAP-IV Swanson, Nolan and Pelham-IV question-
naire
◂







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 6 of 14Coghill and Seth  Child Adolesc Psychiatry Ment Health  (2015) 9:52 
2b. Diagnosis and treatment planning
Once the required information has been gathered, a 
standardized assessment report (Additional file  4) is 
compiled and forwarded to a senior clinician (usu-
ally a consultant or associate specialist/higher spe-
cialist trainee), who will review the information and 
arrange an “end of assessment” appointment with the 
patient and their family to discuss diagnosis and treat-
ment planning. Whilst it is often possible to conclude 
the ADHD assessment while awaiting the outcome of 
additional information, it is sometimes necessary to 
delay this meeting until all data are available. The core 
CAMHS worker who conducted the initial assessment 
does not usually need to attend, but this may be helpful 
in complex cases. At this meeting, the consultant does 
not spend valuable time revisiting issues that have been 
adequately covered during the assessment; rather he/
she aims to address any outstanding uncertainties, pro-
vide a diagnosis and formulation and agree a manage-
ment/treatment plan.
Both the International Classification of Diseases (ICD-
10) [5] and the Diagnostic and Statistical Manual of Men-
tal Disorders 5 (DSM-5) [4] definitions of hyperkinetic 
disorder (HKD)/ADHD are considered during diagnosis, 
respectively. The ICD definition of HKD is more restric-
tive than DSM-defined ADHD and requires that inatten-
tive, hyperactive and impulsive symptoms are all present 
and are both pervasive and impairing. While symptoms 
must also be pervasive and impairing in DSM-defined 
ADHD, the requirements are less strict and DSM-defined 
ADHD includes less severe cases than HKD [4, 5]. If 
ADHD or HKD is diagnosed, the focus for the remain-
der of the meeting is to provide psychoeducation about 
ADHD and any co-existing problems, and to discuss the 
various treatment options available. Written information 
and suggestions for web-based support materials are pro-
vided to support these discussions.
Initial treatment decisions generally follow the rec-
ommendations of the SIGN [18], NICE [16, 30, 31] and 
European guidelines [20, 21, 23–25]. Initial therapy 
depends on symptom severity, circumstances, comorbid-
ities, patient preference and parent/carer preference [16], 
and usually includes recommendations for school inter-
ventions. Treatment options include non-pharmacologi-
cal interventions and pharmacotherapies.
If ADHD is not diagnosed, any other mental health 
problems that have been identified will be discussed 
and appropriate arrangements made for follow-up or 
discharge.
3. Initiating treatment
The initial focus of treatment is to reduce the core symp-
toms of ADHD. Medication is usually offered as first-line 
treatment for patients aged 6  years and over who meet 
ICD-10 criteria for HKD (Fig.  2). Non-pharmacological 
treatment, consisting primarily of parenting interven-
tions that focus on behavioural management, is generally 
recommended for children under 6  years of age, those 
who meet DSM criteria for ADHD but not ICD criteria 
for HKD and those whose parents are resistant to medi-
cation options. Parenting programs readily available 
in Dundee include: New Forest Parenting Programme 
(NFPP) [43], Triple P [44] and Incredible Years [45]. If the 
treatment response to a parenting intervention is consid-
ered adequate, the need for additional interventions to 
address any remaining difficulties is assessed and follow-
up in the continuing care clinic is arranged (see below for 
further details). If the treatment response is inadequate, 
further treatment options are discussed; typically involv-
ing medication.
Initiating and titrating medication for ADHD
Initial medication options The choice of first-line medi-
cation is informed by clinical guidelines [16–18, 20, 21]. 
Table 3 Priority waiting list: factors indicating the prioritization of a patient with a development disorder
These criteria were designed to identify the ~10 % of patients with the most immediate needs. Patients from priority and routine waiting lists are routed into the 
assessment process in a 1:1 ratio; however, this ratio could be altered in favour of either waiting list depending on demand
CAMHS Child and Adolescent Mental Health Service
Trigger for prioritization
Placement (with own family or out-of-family) at significant risk of breakdown and seeing the patient may reduce this risk and social workers are already 
appropriately involved
Significant health risk will ensue for a patient’s caregiver and/or family members if the patient does not receive treatment
Patient at risk of significant, deliberate self-harm
Patient at significant risk of developing an impairing comorbid disorder (not oppositional defiant disorder or conduct disorder)
Substantial reduction in school attendance has occurred due to multiple or extended exclusions or the patient has significantly reduced access to 
educational opportunities: e.g. a long-term part-time timetable or patient can only be taught 1:1 and, in all cases, appropriate educational measures 
are already in place
Patient approaching upper age-limit of the service (≥15.5 years for Dundee CAMHS)
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In most cases, a stimulant medication is the first choice and 
methylphenidate is most commonly prescribed. Primary 
school-age children (up to 11 years) usually begin treat-
ment with immediate-release methylphenidate (which is 
less expensive—a priority for publically funded services—
more flexible and has a short duration of adverse events), 
whereas older children usually start with a long-acting for-
mulation (which is less stigmatizing and has a lower risk of 
diversion as medication is not taken during school hours). 
For patients with tic disorders, issues with substance mis-
use or a strong family preference to avoid stimulants [16], 
atomoxetine may be considered as a first-line treatment.
Dose titration As informed by the MTA study and in 
line with clinical guidelines, the DACCP places consid-
erable importance on accurate dose titration, with the 
aim of achieving maximum benefit with minimal adverse 
effects. Maximum benefit is prioritized over minimum 
dose. A 4-week, structured dose-optimization schedule is 
used for all patients prescribed immediate-release stimu-
lants or extended-release methylphenidate. The dose is 
increased from 5 to 20 mg three times per day for imme-
diate-release formulations or equivalent dose for long-
acting formulations. Medication is usually initiated with 
12-h cover, 7 days a week, without routine drug holidays.
Baseline and titration appointments are nurse led 
(although a senior clinician is always available for advice 
and to write prescriptions, if required) and last approx-
imately 30  min. During the baseline appointment, 
patients are informed of the purpose of titration, the 
schedule is agreed and baseline assessments performed 
(see below). Three or four titration appointments are typ-
ically required, depending on the medication and clinical 
response. Titration appointments are conducted face-to-
face or by telephone (in which case local health services 
may need to perform weight, pulse and blood pressure 
assessments). The patient is reviewed jointly by a nurse 
Fig. 2 DACCP treatment algorithm: selection of pharmacological versus non-pharmacological therapy for patients with ADHD. aFor the evaluation 
of treatment response, please refer to section ‘How do we define optimal/adequate/inadequate response?’. For non-pharmacological therapy, treat-
ment response is reviewed at the end of a course of therapy (programmes are usually 10–12 sessions) and annually thereafter. The use of medica-
tion as first-line treatment does not preclude combining this with a non-pharmacological approach]. ADHD attention-deficit/hyperactivity disorder, 
DACCP Dundee ADHD Clinical Care Pathway, HKD hyperkinetic disorder, ICD International Classification of Diseases
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and a physician at the end of the 4-week period and they, 
in discussion with the family, agree on the ongoing medi-
cation and dose.
In addition to clinical feedback from the patient and 
parent/carer, the following information is gathered using 
standardized documentation at baseline and each subse-
quent titration appointment (Additional files 1, 5):
  • ADHD-RS-IV or SNAP-IV, administered as a semi-
structured interview and rated by the clinician.
  • SKAMP report, completed by the patient’s teacher.
  • Clinical Global Impression-Severity and -Improve-
ment rating scales.
  • Children’s Global Assessment Scale.
  • Structured assessment of ‘other symptoms’. Although 
the purpose is to identify treatment-related adverse 
effects, we ask patients ‘Do you have these symp-
toms?’ and ‘Are they impairing?’ rather than ‘Did 
medication cause these problems?’. The clinician then 
decides whether any identified symptoms are likely 
related to medication or the underlying ADHD.
  • Weight, blood pressure and pulse rate.
Assessment of symptom control and tolerability Medica-
tion doses are increased at each visit, unless symptoms 
are already under optimal control (indicated by a mean 
post-treatment score of ≤1 for ADHD-RS-IV or the 
ADHD questions from SNAP-IV; see section on defin-
ing adequate/inadequate response below and Table 2) or 
there are significant adverse effects. When symptom con-
trol is considered optimal, the end-of-titration appoint-
ment is usually brought forward and the dose maintained. 
The patients exiting titration are booked into a continuing 
care clinic approximately 3 months later, and prescribing, 
but not monitoring, is transferred relatively quickly to pri-
mary care under a shared-care agreement.
If a patient experiences adverse effects, the dose is usu-
ally decreased, but may be either continued for another 
week or increased as originally scheduled to assess treat-
ment benefit versus adverse effects.
If there has been no clinical response to a maximum 
dose (usually 20  mg methylphenidate tds or equiva-
lent) or the patient has experienced significant adverse 
effects, switching to an alternative medication or a dif-
ferent approach is considered (described further below). 
A full discussion of the management of adverse effects 
is beyond the scope of this article; interested readers are 
directed to Cortese et al. [23] for further information.
How do we define optimal/adequate/inadequate response?
Individual response to ADHD therapy is influenced 
by a number of factors, including severity of the dis-
order, sensitivity to a specific treatment, vulnerability 
to treatment-related adverse effects, and personal val-
ues and preferences regarding treatment outcome [46]. 
Indeed, the perception of treatment response is sub-
jective and thus may differ depending on the reporter. 
In the DACCP, information on treatment response is 
always gathered from both the patient and the parent/
carer, using a semi-structured interview. During titra-
tion, good symptom control is considered the key out-
come by the DACCP.
Using a combination of clinical data, published norms, 
the results of clinical trials and established statisti-
cal methods [47], we calculated a clinically meaning-
ful cut-off score for the ADHD-RS-IV when used as a 
semi-structured interview. This, combined with clini-
cal experience and published data, has suggested scores 
associated with different clinical states. The mean 
(standard deviation [SD]) ADHD-RS-IV total score for 
untreated individuals with ADHD was reported as 41.8 
(8.3) in the UK [48]. In general, a decrease in total score 
of >11 from baseline suggests a clinically meaningful 
response. As the ADHD-RS-IV and the ADHD section of 
SNAP-IV are very similar, it seems likely that the same 
scoring rules can be applied to SNAP-IV.
The clinical significance of post-treatment reductions 
in ADHD-RS-IV and SNAP-IV scores are thoroughly 
described in Table 2. Although these definitions are used 
to guide clinical decision-making, they must be applied 
flexibly, and the final judgement of the adequacy of treat-
ment response requires clinical judgement and consid-
eration of all available information.
Treatment switching
Of those children with ADHD, 70–80 % respond well to 
either methylphenidate or d-amphetamines and 90–95 % 
respond to at least one class of stimulant [49–53]. 
Where a patient is judged to have an inadequate clini-
cal response to methylphenidate at the end of titration, 
switching to lisdexamfetamine or atomoxetine is usually 
recommended and the titration process repeated. Titra-
tion of lisdexamfetamine is similar to that of methylphe-
nidate, but with three rather than four dose steps (30, 50 
and 70 mg). Titration of atomoxetine begins with a dose 
of 0.5 mg/kg for 1 week, then increased to 1.2 mg/kg for 
at least 12  weeks (unless there are intolerable adverse 
effects) to fully assess the benefits. The dose is increased 
to 1.8 mg/kg if there is only a partial response.
4. Continuing care/monitoring treatment
Although titration and optimization of the initial response 
to medication are important, data from the MTA suggest 
that close attention to continuing care is also essential 
[12]. Accordingly, all patients on the DACCP, regardless 
of medication status, are followed up. The purpose of 
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continuing care clinics is to monitor and adjust ADHD 
treatments and to identify any ‘other problems’ that will 
require additional sessions for further assessment or 
treatment [12]. Continuing care clinics are nurse led but a 
senior clinician (consultant or associate specialist/higher 
specialist trainee) is always available to discuss proposed 
changes to treatment, review patients with particularly 
complex issues and/or discuss stable patients who do not 
require changes to care after the clinic has finished. Clin-
ics are conducted by the patient’s core worker if possible 
for continuity of care. Each appointment is scheduled for 
45 min. Up to six clinics are held simultaneously to make 
the best use of senior clinicians’ time.
For patients receiving medication, the typical inter-
val between review appointments is 6 months; however, 
more frequent appointments are available as necessary. 
Annual reviews are conducted for patients receiving 
non-pharmacological interventions. Patients who are not 
being actively treated are also followed up at least annu-
ally as it is not uncommon for these patients to experi-
ence renewed difficulties, especially at times of transition 
(e.g. moving from primary to secondary school) or stress 
(e.g. periods of family discord).
Continuing care clinics use the same structured data 
collection instruments and standardized assessment tools 
used during medication titration (Additional file 5). How-
ever, there is a change of emphasis to collect information 
on medication issues (such as breakthrough symptoms), 
adherence and stigmatization, in addition to the stand-
ard clinical outcomes collected during titration. During 
this treatment phase, we also placed increased emphasis 
on the broader picture, such as comorbid mental health 
issues, physical problems, learning difficulties, ongoing 
functional impairment and quality of life, including peer 
and family relationships, school and academic progress 
and social life. Identified issues are assessed using stand-
ardized instruments and assessments as appropriate 
(Additional file 3).
The identification of these ‘other problems’ is the key 
to providing good quality holistic care for patients with 
ADHD. Typical issues include:
  • assessment of sleeping or eating difficulties
  • assessment of mood or anxiety problems
  • liaison with schools or other agencies
  • assessment of the need for parent training or other 
psychological interventions
  • discussion of complex medication issues
  • cognitive testing
  • occupational therapy assessment.
Some of the simple problems, such as sleep and eat-
ing difficulties, can be managed within the continuing 
care clinic appointment. However, time constraints mean 
additional appointments are often required to focus on 
identified issues. These appointments are arranged either 
with the core worker or as a specific ‘asked-to-see’ assess-
ment with an appropriate team member (e.g. a clinical 
psychologist, dietician or physician).
Outcomes of the DACCP
Clinical pathways need to demonstrate positive out-
comes. As noted previously, the DACCP received favour-
able reviews from the Healthcare Improvement Scotland 
2008 and 2012 audits of ADHD services across Scotland 
[15, 54]. These reflect the DACCP’s implementation 
of and adherence to the SIGN clinical practice guide-
lines [18]. In addition, clinical outcomes are routinely 
reviewed by the DACCP team. For example, from a ran-
dom sample of 150 patients currently in continuing care, 
96 % (144/150) are receiving pharmacological treatment, 
most commonly methylphenidate (83  %; 119/144), fol-
lowed by lisdexamfetamine (9  %; 13/144) and atomoxe-
tine (8 %; 12/144). The remaining 4 % (6/150) of patients 
are unmedicated. Overall, our clinical outcome data sup-
port the use of the DACCP and provide evidence that 
we can replicate improvements in ADHD symptoms 
observed in clinical trials within a real-world setting. For 
example, among the 119 patients currently in continu-
ing care and receiving methylphenidate (Table  4), their 
mean (SD) total ADHD-RS-IV item score at baseline was 
2.5 (0.4), and none had a mean item score of ≤1, indi-
cating a severely impaired population (see Table  2 for 
clinical interpretation of scores). Mean (SD) item score 
decreased to 0.7 (0.4) at the end of titration (best dose), 
indicating a strong clinical response and 80 % of patients 
had a mean item score of ≤1. At the most recent clinic 
visit, mean (SD) total ADHD-RS-IV item score remained 
low at 0.8 (0.8), although the average score across all 
post-titration continuing care visits was slightly higher 
(1.0 [0.6]). The mean total ADHD-RS-IV score decreased 
by 29.4 points from baseline to their most recent visit. 
This is in line with changes in total ADHD-RS-IV scores 
observed in a rigorously conducted randomized clini-
cal trial of European children and adolescents treated 
with stimulant ADHD medication for 7  weeks [55]. In 
this study, the mean (SD) total ADHD-RS-IV scores at 
baseline for patients treated with lisdexamfetamine or 
methylphenidate were 41.0 (7.3) and 40.4 (6.8), respec-
tively, and least squares mean reductions (standard error) 
from baseline to endpoint were 24.3 (1.2) and 18.7 (1.1), 
respectively [55].
Furthermore, we found no significant associa-
tions between ADHD-RS-IV subscale and total scores 
with duration of treatment, which ranged from 1 to 
119  months, suggesting that with careful management, 
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methylphenidate may be effective for long-term treat-
ment of ADHD symptoms.
Staff and training
The DACCP is funded by the NHS from the core 
CAMHS budget and staffed by employees from within 
the general CAMHS service. Limited resources in the 
Dundee CAMHS require us to make best use of available 
staff. Therefore, much of the clinical work is nurse led, 
which allows multiple clinics to be held simultaneously 
and streamlines demand on senior clinician’s time.
At present, there are no dedicated ADHD staff mem-
bers. Each full-time nurse in the service is involved with 
assessments and dose titrations and provides ongoing 
continuing care for about 50–70 patients. This accounts 
for approximately 60  % of their working week. Most 
nurses leading the DACCP clinics are not qualified to 
prescribe ADHD medications. Senior medical cover is 
provided by doctors with specialist training and experi-
ence in either child psychiatry or paediatrics, each con-
tributing 1–1.5 days per week, comprising approximately 
one full-time equivalent. All clinicians working within 
the DACCP have had prior experience in general child 
and adolescent mental health or paediatrics. Junior doc-
tors (doctors in training) are involved when available, 
and contributions from clinical psychology, occupational 
therapy and a dietician are made as required.
A multidisciplinary team of experienced clinicians 
provide supervision and training to new and junior staff 
on the assessment and management of ADHD, recogni-
tion and assessment of common coexisting difficulties, 
and measurement of clinical outcomes. All new staff 
members receive formal classroom training on how to 
conduct assessments, dose titration and continuing care 
appointments, and the use of standardized instruments 
to evaluate clinical outcomes. However, most training is 
conducted within the clinic by observation of consulta-
tions with senior nursing medical staff; new staff shadow 
an experienced clinician until considered competent 
to work independently. The training period lasts up to 
3 months for nurses and typically around 4 weeks for jun-
ior doctors. All staff are updated when new information 
on ADHD becomes available.
Translation of DACCP into other healthcare systems
The DACCP has proved to be robust in the face of sub-
stantial changes to the CAMHS service. Each succes-
sive organizational framework has presented challenges. 
For example, the workflow-based CAPA model [36] was 
not designed to incorporate the volume of patients seen 
by ADHD services and, in direct contrast to our path-
way, tends to emphasize quantity over quality. We are 
currently reviewing the implementation of CAPA and 
it is likely that ADHD care will move out of the CAPA 
Table 4 Clinical outcome data for  patients with  ADHD in  continuing care receiving methylphenidate (random sample; 
N = 119)
Data presented at the 5° Simpósio Perturbação de Hiperatividade e Défice de Atenção, Coimbra, Portugal, 16–17 April 2015, and available online at 
 http://discovery.dundee.ac.uk/portal/files/6693836/optimizing_treatment_for_ADHD_dc.pdf. Included by permission of the author
ADHD attention-deficit/hyperactivity disorder, ADHD-RS-IV attention-deficit/hyperactivity disorder rating scale IV, MPH methylphenidate, n/a not available,  
SD standard deviation
a Calculated by dividing the total/subscale score by the number of items (9 for each subscale; 18 for the total)
b Pre-treatment (all patients were naïve to ADHD medication)
c Mean scores over all (post-titration) continuing care visits
d Pearson correlation between time in treatment (months) and ADHD-RS-IV subscale and total scores at most recent clinic visit: Inattention, rho = –0.197, p = 0.07; 
























Total score Mean item 
scorea
n (%)
Baselineb n/a n/a 21.8 (4.3) 2.4 (0.5) 22.4 (4.3) 2.5 (0.5) 44.2 (6.9) 2.5 (0.4) 0 (0)
End of titration 
(best dose)
n/a 45.3 (14.0) 6.2 (4.1) 0.7 (0.5) 6.2 (4.1) 0.7 (0.5) 12.2 (7.7) 0.7 (0.4) 95 (80)
Most recent 
clinic visit





51.8 (14.4) 9.2 (4.2) 1.0 (0.5) 8.8 (4.6) 1.0 (0.6) 18.0 (8.4) 1.0 (0.6) 57 (48)
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workflow and run in parallel; a move that would be 
strongly supported by the authors.
The pathway has continued to develop in light of new 
evidence, experience and ideas from staff. The ethos 
within the pathway is to be change-orientated and prob-
lem-solving in its approach. Changes are often imple-
mented as a result of new findings in the literature or 
the licensing of a new treatment, but frequently also 
suggested by a team member and then problem solved 
by the team, implemented, reviewed and audited, with 
further changes made as required. Examples of changes 
include; the adoption of a slimmed down approach to 
titration appointments to ensure that time is used effi-
ciently during this stage of treatment; the development 
of an electronic version of the clinic documentation that 
interfaces with the electronic patient record and facili-
tates comparison of treatment outcomes and vital signs 
over time; the implementation of titration protocols for 
new medications (e.g. the non-stimulants and lisdexam-
fetamine) that were not available when the pathway was 
originally designed; and the introduction of locally devel-
oped blood pressure centile charts and implementation 
of the algorithm for managing increased blood pressure 
as proposed by the European ADHD Guidelines Group 
[56]. However, notwithstanding these changes, the core 
of the DACCP has remained essentially intact since its 
inception, demonstrating the generalizability of the path-
way and the capacity for translation into other healthcare 
systems.
The DACCP is protocol-driven but flexible. Impor-
tantly, the protocols are not profession-specific, allowing 
best use of the staff available. Nurse-led clinics are clini-
cally- and cost-effective within our setting. In healthcare 
systems where only doctors are able to manage ADHD, 
these protocols facilitate rapid training and establish con-
sistent standards of care.
Some elements of the DACCP may not translate into 
other healthcare systems so easily. For example, the 
DACCP is strongly multidisciplinary and this brings 
many benefits. For services where such multidisciplinary 
working within a clinical team is more difficult, we would 
suggest discussing opportunities for virtual teams with 
agreed cross-referral protocols.
Another commonly discussed problem concerns the 
assessment of psychiatric comorbidities within a non-
psychiatric setting. Clinical guidelines are in agree-
ment that integration of assessment of comorbidities 
into ADHD work-up is essential. To facilitate this, we 
have successfully trained paediatricians and paediatric 
nurses to conduct a full mental health assessment, typi-
cally using structured and semi-structured interviews 
such as the Development and Well Being Assessment 
and K-SADS-PL. Once comfortable and confident with 
this structured approach they will switch to our system-
atic (but less structured) assessment protocol described 
above (Additional file 2). An alternative approach would 
be to use a screening questionnaire such as the Strengths 
and Difficulties Questionnaire [57] or Child Behav-
iour Checklist [58] to identify patients with possible 
comorbidities and make any necessary arrangements 
for patients to be further assessed by an appropriately 
trained specialist.
A further issue concerns the prescription of medi-
cations. Unlike in the UK, this may not be delegated to 
nurses in some countries (although the use of experi-
enced doctors as described above may assist here). Many 
tasks are already performed by case managers other 
than the physician, and private practices are encouraged 
to establish multidisciplinary teams. At the same time, 
enormous differences in terms of acceptance and treat-
ment approaches continue to exist, not only between 
European countries, but also between regions within 
those countries. The sharing of best practice and the 
creation of treatment pathways based on clinical and sci-
entific evidence could help institutions to improve their 
standards.
Our clinic documentation and the SKAMP teachers 
rating scale are available as online Additional files. Alter-
native documentation is available from the Canadian 
ADHD Resource Alliance [59]. Their assessment toolkit 
has many similarities to our own and may be preferred by 
some clinicians [60].
Administrative aspects to consider when implementing 
a pathway based on the DACCP principles are the need 
for a good organization to ensure the necessary forms 
and instruments are available for distribution, and that 
systems are in place to follow-up with schools regarding 
the return of questionnaires and reports.
Conclusions
The DACCP uses staff skills and time effectively via a 
structured core pathway to provide a consistent, up-
to-date, evidence-based approach to the treatment and 
management of children and adolescents with ADHD. 
The DACCP uses standard protocols for the assessment, 
titration and routine monitoring of clinical care and 
treatment outcomes. The pathway provides effective care 
in a real-world setting and has demonstrated success in 
the long-term management of ADHD. As with any clini-
cal pathway, there are limitations; it is time-intensive and 
requires well-trained staff. However, we believe that the 
need for this standard of care is evident and that patients 
with ADHD should be managed within a pathway that 
strives for optimal care. While the pathway is continu-
ally developing, it has remained essentially intact, dem-
onstrating its flexibility and capacity for translation into 
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other healthcare systems. However, we continually strive 
to improve the efficiency of our service without compro-
mising clinical standards.
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